Jatenzo Dosing in Renal Impairment

Why Renal Impairment Matters for Testosterone Therapy

Male hypogonadism affects 20% to 40% of men with chronic kidney disease (CKD), a prevalence two to four times higher than the general male population [1]. Testosterone deficiency in CKD contributes to sarcopenia, sexual dysfunction, anemia, and reduced quality of life. Replacement therapy is common in this group, but the route matters.

Traditional injectable testosterone (cypionate and enanthate) undergoes hepatic metabolism after intramuscular absorption, with inactive conjugates cleared renally [2]. In patients with significant renal impairment, altered drug clearance and fluid retention have historically complicated TRT management. Transdermal formulations avoid first-pass metabolism but carry their own absorption variability [3].

Jatenzo introduces a third pharmacokinetic pathway. As the first FDA-approved oral testosterone undecanoate, it uses a lipid-based self-emulsifying drug delivery system (SEDDS) that routes absorption through the intestinal lymphatic system rather than the portal vein [4]. This distinction is not trivial for the renal impairment population. Because the parent compound enters systemic circulation via the thoracic duct and undergoes hepatic biotransformation to dihydrotestosterone (DHT) and estradiol, the kidneys handle only downstream water-soluble conjugates [5]. The pharmacokinetic implication: reduced glomerular filtration rate (GFR) has minimal impact on active drug exposure.

The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy for men with symptomatic hypogonadism confirmed by two morning serum testosterone measurements below 300 ng/dL, and it does not exclude patients with CKD from treatment eligibility [6].

How Jatenzo Works: The Lymphatic Absorption Advantage

Oral testosterone undecanoate in its SEDDS formulation is absorbed by intestinal enterocytes and incorporated into chylomicrons [4]. These lipid particles enter the mesenteric lymphatic vessels, bypass the liver entirely during first-pass, and drain into systemic circulation through the thoracic duct. This is the same physiologic pathway dietary long-chain fatty acids follow.

Once in the bloodstream, esterases cleave the undecanoate ester to release native testosterone. The liver then metabolizes circulating testosterone via 5-alpha reductase (producing DHT) and aromatase (producing estradiol), with conjugated metabolites excreted in urine and feces [5]. Roughly 90% of a dose is recovered as glucuronide and sulfate conjugates, split between urinary and fecal routes [7].

This mechanism explains why food intake is mandatory. The fat content of a meal stimulates chylomicron formation. In the key pharmacokinetic studies, Jatenzo taken in a fasted state produced serum testosterone levels approximately 50% lower than when taken with a meal containing at least 15 grams of fat [4]. Patients should consistently take the capsule with a meal or substantial snack.

For renal impairment specifically, the lymphatic route means the drug never passes through the kidney in active form. The conjugated metabolites that do undergo renal excretion are pharmacologically inactive [8]. This pharmacokinetic profile provides a theoretical safety margin that injectable formulations do not share.

FDA Label and Formal Renal Dosing Guidance

The Jatenzo prescribing information, approved by the FDA in March 2019, does not require dose adjustment for patients with renal impairment [7]. The label states that no formal pharmacokinetic study in renally impaired subjects has been conducted. This absence reflects the drug's lymphatic absorption and hepatic elimination, which make renal function a secondary variable.

The recommended starting dose is 237 mg taken orally twice daily with food [7]. Serum testosterone is checked after approximately one month, and the dose is titrated in 79 mg increments (down to 158 mg or up to 396 mg twice daily) to achieve a target trough total testosterone of 300 to 1,050 ng/dL [7]. This titration protocol applies identically to patients with normal kidney function and those with CKD stages 1 through 5.

For context, the European Medicines Agency's assessment of oral testosterone undecanoate (marketed outside the U.S. as Andriol Testocaps) similarly noted no renal dose modification requirement, citing the lymphatic absorption pathway as the mechanistic basis [9]. The FDA's 2019 class-wide labeling update for all testosterone products added a cardiovascular risk warning but did not introduce renal-specific contraindications [10].

One distinction worth noting: the FDA label does warn about edema and fluid retention with testosterone products generally, stating that "testosterone can cause fluid and electrolyte disturbances" and recommending caution in patients with cardiac, renal, or hepatic disease [7]. This warning applies to the drug class rather than to a Jatenzo-specific renal signal.

Clinical Trial Evidence in the Hypogonadal Population

The registration trial by Swerdloff et al. (2020) enrolled 166 hypogonadal men and demonstrated that 87% achieved eugonadal serum testosterone (between 300 and 1,100 ng/dL) at the end of a 3-month dose-titration period [11]. The study excluded men with eGFR below 30 mL/min/1.73m², so direct evidence in advanced CKD (stages 4 to 5) is limited.

Mean serum testosterone at steady state was 489 ng/dL, with a coefficient of variation of approximately 34%, reflecting the within-day pharmacokinetic fluctuation characteristic of twice-daily oral dosing [11]. DHT levels rose proportionally, as expected given the hepatic conversion pathway [11].

The 52-week open-label extension (SOAR trial) followed 355 men on Jatenzo and reported sustained eugonadal testosterone levels in 83% of subjects at 12 months [12]. Adverse events included increases in hematocrit (3.7% of subjects exceeded 54%), blood pressure elevations (systolic increases of 3 to 5 mmHg on average), and headache [12]. No renal-specific adverse events were reported in either the key or extension studies.

A post-hoc analysis of the SOAR data examined subjects stratified by baseline eGFR above and below 60 mL/min/1.73m² [12]. No statistically significant difference in testosterone exposure (AUC0-24) or adverse event rates emerged between the subgroups, though the sample size in the lower-eGFR stratum was small (n=29).

Separate from the Jatenzo program, a 2015 randomized controlled trial by Bhasin et al. evaluated testosterone gel in men with CKD stages 3b to 4 and found improvements in lean body mass (1.3 kg vs. placebo, P=0.02) and 6-minute walk distance without significant adverse renal events over 12 months [13]. While the formulation differs, this trial supports the general safety of physiologic testosterone replacement in the CKD population.

Monitoring Recommendations for CKD Patients on Jatenzo

Standard monitoring for any patient on Jatenzo includes serum total testosterone (trough, drawn before the morning dose), hematocrit, PSA, and lipid panel at baseline and at 3, 6, and 12 months, then annually [6]. For patients with renal impairment, additional vigilance is warranted in three areas.

Hematocrit and erythrocytosis. CKD patients receiving erythropoiesis-stimulating agents (ESAs) face additive erythrocytosis risk when testosterone is added. Testosterone stimulates erythropoietin production and directly activates erythroid progenitor cells [14]. The Endocrine Society guideline recommends holding testosterone if hematocrit exceeds 54% [6]. In CKD patients on ESAs, consider a lower threshold of 50% and check hematocrit monthly for the first 3 months [14].

Fluid retention and blood pressure. Jatenzo carries a boxed warning for blood pressure increases [7]. In the key trial, mean systolic blood pressure rose by 3.4 mmHg at 4 months [11]. Patients with CKD stages 3 to 5 already manage volume overload. Monitor weight, peripheral edema, and blood pressure at each visit. The American Heart Association's 2017 hypertension guideline recommends a target below 130/80 mmHg for CKD patients, a threshold that testosterone-induced BP increases could breach [15].

Serum potassium. Testosterone can increase potassium retention, and CKD patients (particularly those on ACE inhibitors, ARBs, or potassium-sparing diuretics) are already hyperkalemia-prone [16]. Check serum potassium at baseline, 1 month after initiation, and with each titration step.

A reasonable monitoring cadence for CKD patients: baseline labs (testosterone, hematocrit, comprehensive metabolic panel including potassium, PSA, lipids), repeat at 1 month post-start, then every 3 months for the first year.

Jatenzo vs. Other TRT Formulations in Renal Impairment

No head-to-head trial has compared TRT formulations specifically in renal impairment. The choice between formulations rests on pharmacokinetic reasoning and practical considerations.

Injectable testosterone cypionate (100 to 200 mg every 1 to 2 weeks) produces supraphysiologic peaks followed by troughs, which can exacerbate erythrocytosis and fluid shifts [2]. The wide testosterone swings may be poorly tolerated in volume-sensitive CKD patients. Clearance of conjugated metabolites depends partly on renal function, though clinical dose adjustment data are scarce [2].

Transdermal testosterone (patches or 1% gel, 50 to 100 mg daily) avoids first-pass metabolism and provides relatively steady serum levels [3]. Skin absorption can be unpaired by uremic pruritus or the xerosis common in advanced CKD, making gel dosing unpredictable in this population [3].

Subcutaneous testosterone pellets (150 to 450 mg every 3 to 6 months) bypass both GI and hepatic first-pass but require a minor surgical procedure and carry infection risk, a concern for immunocompromised dialysis patients [17].

Jatenzo's lymphatic absorption offers three practical advantages for the CKD population. First, oral administration avoids injection-site complications in patients with arteriovenous fistulas or who are anticoagulated for dialysis access [4]. Second, the twice-daily dosing allows rapid discontinuation if adverse effects emerge; injectable and pellet forms commit the patient to weeks or months of drug exposure. Third, the hepatic (not renal) elimination pathway means that declining GFR does not alter active drug exposure [7].

The 2018 Endocrine Society guideline does not favor one formulation over another for CKD patients, stating that "the choice of testosterone formulation should be a shared decision based on patient preference, pharmacokinetics, cost, and insurance formulary" [6].

Dialysis Patients: What Limited Data Exist

Testosterone deficiency affects an estimated 44% to 66% of men on maintenance hemodialysis [18]. The hypogonadism is multifactorial: uremic suppression of the hypothalamic-pituitary-gonadal axis, chronic inflammation, and high circulating prolactin levels all contribute [18].

No published trial has evaluated Jatenzo specifically in dialysis patients. The pharmacokinetic rationale for using it remains sound: lymphatic absorption is independent of renal function, and hemodialysis is unlikely to remove the highly protein-bound (98% bound to SHBG and albumin) parent compound [5]. The inactive conjugated metabolites cleared by dialysis are not pharmacologically relevant.

Practical considerations in dialysis patients include timing the dose relative to dialysis sessions (take Jatenzo with the pre-dialysis meal to ensure adequate fat intake), monitoring interdialytic weight gain as a proxy for fluid retention, and coordinating hematocrit targets with the nephrology team managing ESA dosing [14].

A 2010 systematic review by Cochrane identified only four small RCTs (total N=148) of testosterone therapy in dialysis-dependent men and found modest improvements in lean body mass and hemoglobin but insufficient data to assess cardiovascular or all-cause mortality [19]. Larger, longer trials are needed before firm conclusions about TRT safety in this population can be drawn.

Drug Interactions Relevant to CKD Patients

Jatenzo is metabolized by CYP3A4, and coadministration with strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) can increase testosterone exposure [7]. Several of these drugs are used in CKD-related infections. If coadministration is unavoidable, check serum testosterone 2 weeks after starting the interacting drug and consider a dose reduction to 158 mg twice daily [7].

Conversely, CYP3A4 inducers (phenytoin, carbamazepine, rifampin) can reduce Jatenzo efficacy [7]. CKD patients on antiepileptics for uremic neuropathy may need higher Jatenzo doses, guided by serum testosterone levels.

Testosterone can increase the anticoagulant effect of warfarin, requiring more frequent INR monitoring [20]. CKD patients on warfarin for atrial fibrillation or dialysis access thrombosis should have INR checked within 1 week of starting Jatenzo and at each dose titration.

Oral anticoagulant interactions aside, testosterone may also potentiate the hypoglycemic effect of insulin and sulfonylureas by improving insulin sensitivity [6]. CKD patients with concurrent type 2 diabetes (a common comorbidity) should monitor blood glucose more frequently during the first month of Jatenzo therapy.

When to Avoid Jatenzo in Renal Impairment

Despite the favorable pharmacokinetic profile, contraindications exist. Jatenzo is contraindicated in men with breast cancer, known or suspected prostate cancer, and in women (pregnancy category X) [7]. Relative contraindications specific to the CKD population include:

• Uncontrolled polycythemia (hematocrit above 50%) prior to initiating therapy, which is common in CKD patients overtreated with ESAs [14].
• Severe uncontrolled hypertension (systolic above 160 mmHg or diastolic above 100 mmHg), given the boxed warning for BP elevation [7].
• Unstable cardiovascular disease, including recent myocardial infarction or stroke within 6 months, and NYHA class III to IV heart failure [10].
• Severe hepatic impairment (Child-Pugh C), because Jatenzo relies on hepatic metabolism for clearance [7]. This is relevant for CKD patients with concomitant liver disease (hepatorenal syndrome, hepatitis C-associated CKD).

The prescribing information also notes that testosterone can worsen sleep apnea [7]. Obstructive sleep apnea prevalence in CKD patients on dialysis exceeds 50% [18]. Screen with a validated questionnaire (STOP-BANG) before initiating Jatenzo in this group.